Blog
Unlocking Hidden Value in Established Brands Portfolio
Thomas Steffen, Principal Strategy Consulting, IQVIA
Martin Bate, Head of HCP Engagement, Commercial Engagement Services
Aleksandra Tarnowska, Engagement Manager, Commercial Engagement Services, IQVIA
Sep 02, 2025

In a pharmaceutical world captivated by new launches and breakthrough therapies, established brands—those on the market for over a decade—often fade into the background. Yet these mature assets are far from obsolete. For the top 20 pharma companies, they represent 40–60% of revenue and over 60% of global sales1. When managed strategically, they can become the backbone of long-term portfolio sustainability.

But established brands face mounting pressures: loss of exclusivity (LoE), pricing reforms, environmental mandates, and shifting global market dynamics. To help pharma companies navigate these challenges, IQVIA offers a flexible, data-driven Established Brands Optimization (EBO) approach — a modular, pick-and-mix solution tailored to each client’s needs.

IQVIA’s EBO Approach: Analyze. Strategize. Execute.

Optimizing established pharma brands requires more than tactical adjustments. It demands a structured, scalable, and data-backed playbook. IQVIA’s approach combines deep market intelligence with tailored execution, ensuring every decision is grounded in data and geared for growth.

Analyze: Uncover hidden opportunities through multifaceted assessment

This initial step involves a holistic audit of your portfolio, markets and operational realities. The goal is to surface untapped value by evaluating brands through multiple critical lenses:

  • Brand performance. Understand the sales trajectory, profitability, brand equity, and promotional sensitivity of each established product.
  • Market dynamics. Examine market-specific drivers such as regulatory pressures, competitive intensity and healthcare provider (HCP) influence.
  • Channel and access analysis. Assess how each brand reaches the patient or consumer—via retail, tender, institutional, or hospital—and what gaps exist.
  • Portfolio synergies and complexity. Identify redundancies, underperforming stock keeping units (SKUs) , or brands that add disproportionate operational burden.

Strategize: Align goals with realistic, prioritized actions

This includes segmentation of brands by lifecycle stage, growth potential and operational complexity to define tailored interventions. Strategizing should focus on:

  • Selecting value levers. Choose from enhancing sales, simplifying complexity, improving gross to net (GTN) and optimizing promotional spend—based on feasibility and expected return.
  • Defining operating models. Options include in-house management, outsourced promotion, co-promotion, or digital-only hubs. The right model will depend on regional constraints, brand maturity and internal resource availability.
  • Establishing governance. Implement key performance indicators (KPIs), reporting protocols and clear ownership to ensure accountability and adaptability.

Execute: Operationalize strategy with precision and agility

Value is realized in the execution phase, which involves translating strategic priorities into targeted and measurable actions, while adjusting for evolving dynamics across processes and platforms. Execution activities typically include:

  • Capability planning. Determine the optimal mix of sales, marketing, digital engagement and access roles based on chosen operating models.
  • Initiative deployment. Launch brand enhancements, new access models, digital campaigns, or third-party commercial partnerships as appropriate.
  • Performance monitoring and optimization. Track KPIs in real-time—such as HCP coverage, promotional return on investment and margin impact—to recalibrate the approach dynamically.

Execution should be both centralized and localized, leveraging global efficiencies while respecting regional regulations and HCP engagement norms.

IQVIA’s Established Brand Optimization enhances established brand portfolio value through a structured, actionable strategy. Its end-to-end full commercial outsourcing solution offers a modular suite of services, that can be tailored to geographic and operational needs.

IQVIA EBO in Action: Risk-Sharing Success

A major pharma company with a broad portfolio of established brands sought to refocus internal resources on its pipeline. Through a global outsourcing agreement covering 15 brands across six therapeutic areas, promotional responsibilities were transferred to a partner at no upfront cost. IQVIA financed activities and earned based on performance, resulting in €100 million in incremental sales over four years. This model improved HCP coverage, reduced complexity, and freed resources for new launches.

Looking Ahead: A Strategic Imperative

As the life sciences landscape continues to shift, established brands are emerging as critical drivers of sustained revenue. With $192 billion in sales projected to lose exclusivity by 2028—twice the impact seen in the previous five years1—the imperative to act is clear.

IQVIA’s Established Brands Optimization (EBO) approach offers a scalable, data-driven path to unlock value from mature portfolios. By combining deep analysis, strategic alignment, and disciplined execution, pharma leaders can transform legacy brands into engines of growth.

Market dynamics won’t wait. Discover how IQVIA EBO  can maximize the full potential of your mature brands portfolio —connect with our EBO experts today to explore tailored strategies.

 

Reference
1. IQVIA Institute – 2025 Indicators of Progress for the Life Sciences Sector, IQVIA Analysis

Is your established brand performing at its peak?
Contact us and discover how IQVIA’s Established Brands Optimization can unlock new growth and profitability.
Follow the Commercial Solutions LinkedIn page for quick updates on our latest offerings, insights, and industry news.

Related solutions

Contact Us